Genmab AS

GMAB: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|fPjLOCK|%M%^LOCK|>j@h!@R

Genmab Earnings: Royalty Revenue Sustains Near-Term Growth With Pipeline Advancement in Progress

Genmab's third-quarter revenue totaled $1.02 billion, increasing 25% year over year. Management reaffirmed the company's 2025 company outlook, expecting revenue between $3.5 billion and $3.7 billion.

Sponsor Center